Pharmaceutical Business Intelligence

  • Formulary management
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 3,726,919

« Back to Dashboard

Summary for Patent: 3,726,919

Abstract:Benzene derivatives of the formula: ##SPC1## Wherein R.sup.1 represents alkanoylamino of not more than nine carbon atoms, R.sup.2 represents alkyl of one through six carbon atoms, and R.sup.3 represents alkyl of one through six carbon atoms or cycloalkyl of three through six carbon atoms, possess pharmacodynamic properties and are useful in the treatment of various cardiac disorders. Moreover, they can be used as starting materials for corresponding compounds in which the ketone group --COR.sup.2 is replaced by a grouping ##SPC2## Wherein R.sup.4 represents, for example, a hydroxy group, or an optionally substituted ureido or thioureido group, which possess similar pharmacodynamic properties.
Inventor(s): Wooldridge; Kenneth Robert Harry (Brentwood, EN), Basil; Berkeley (Highwood, Near Chelmsford, EN)
Assignee: May & Baker Limited (Dagenham, Essex, EN)
Application Number:04/785,403
Patent Claim Types:
see list of patent claims

No matches for this query

Foreign Priority and PCT Information for Patent: 3,726,919

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom58,516/67Dec 22, 1967
United Kingdom56,513/68May 14, 1968
United Kingdom37,103/67Aug 2, 1968

International Patent Family for Patent: 3,726,919

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria286262► Subscribe
Austria286963► Subscribe
Austria289826► Subscribe
Austria292671► Subscribe
Belgium715205► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.